We are accelerating the identification and lead optimization of chemokine analogues and other small proteins. Current efforts are focused on the identification of novel chemokine analogues for the treatment of other serious diseases.
Recognized
Leadership
We will be at the J.P. Morgan Healthcare Conference – January 13-16, 2020. It is the largest healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies,
Ottawa, Canada, Jan. 21, 2020 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage biotechnology company, today announced that it has executed a definitive agreement with the University of
OTTAWA, Ontario, November 12, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd. today announced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors. Dr. Hecht brings extensive expertise
OTTAWA, Ontario, October 31, 2019 (Newswire.com) – Orion Biotechnology Canada, Ltd. today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer. The study
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
CONTACT: info@orionbiotechnology.com
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
